Bio Solution Co.,Ltd. (KOSDAQ:086820)
South Korea · Delayed Price · Currency is KRW 6,560.00
+160.00 (2.50%)
At close: Sep 9, 2026
Bio Solution Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
Operating Revenue | 17,394 | 15,200 | 12,889 | 7,744 | 8,882 |
Other Revenue | - | - | - | - | 0 |
| 17,394 | 15,200 | 12,889 | 7,744 | 8,882 | |
Revenue Growth | 30.88% | 17.93% | 66.43% | -12.81% | - |
Cost of Revenue | 5,998 | 5,632 | 4,760 | 3,498 | 3,033 |
Gross Profit | 11,396 | 9,568 | 8,128 | 4,246 | 5,850 |
Selling, General & Admin | 7,678 | 6,616 | 6,442 | 3,541 | 3,436 |
Research & Development | 6,179 | 6,306 | 5,755 | 3,230 | 3,645 |
Amortization of Goodwill & Intangibles | 85.23 | 67.91 | 40.29 | 91.39 | 84.54 |
Other Operating Expenses | 35.66 | 34.9 | 35.26 | 147.87 | 137.2 |
Operating Expenses | 14,762 | 13,909 | 13,197 | 7,576 | 7,717 |
Operating Income | -3,365 | -4,341 | -5,069 | -3,330 | -1,868 |
Interest Expense | -2,592 | -2,814 | -3,133 | -40.48 | -52.6 |
Interest & Investment Income | 321.92 | 387.28 | 1,496 | 1,427 | 859.13 |
Earnings From Equity Investments | -623.82 | -435.58 | -2,229 | - | - |
Currency Exchange Gain (Loss) | 338.83 | -10.64 | 171.48 | -15.13 | 4.03 |
Other Non Operating Income (Expenses) | 1,918 | 2,613 | 1,791 | 55.51 | 12.08 |
EBT Excluding Unusual Items | -4,003 | -4,600 | -6,973 | -1,903 | -1,045 |
Gain (Loss) on Sale of Investments | 4,883 | 4,883 | -4,883 | 103.52 | 347.5 |
Gain (Loss) on Sale of Assets | -3.44 | -1.2 | 53.69 | - | - |
Asset Writedown | -8.44 | -8.44 | - | - | - |
Other Unusual Items | - | - | -126.07 | - | - |
Pretax Income | 868.96 | 273.36 | -11,928 | -1,800 | -697.54 |
Net Income | 868.96 | 273.36 | -11,928 | -1,800 | -697.54 |
Net Income to Common | 868.96 | 273.36 | -11,928 | -1,800 | -697.54 |
Net Income Growth | - | - | - | - | - |
Shares Outstanding (Basic) | 25 | 24 | 24 | 24 | 24 |
Shares Outstanding (Diluted) | 25 | 24 | 24 | 24 | 24 |
Shares Change | 2.83% | 0.44% | 0.66% | 1.29% | - |
EPS (Basic) | 35.17 | 11.33 | -496.00 | -75.33 | -29.57 |
EPS (Diluted) | 35.14 | 11.32 | -496.00 | -75.33 | -29.67 |
EPS Growth | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
Free Cash Flow | -200.22 | -1,497 | -2,666 | -3,077 | -4,785 |
Free Cash Flow Per Share | -8.10 | -61.96 | -110.86 | -128.79 | -202.87 |
Gross Margin | 65.52% | 62.95% | 63.06% | 54.83% | 65.86% |
Operating Margin | -19.35% | -28.56% | -39.33% | -43.00% | -21.03% |
Profit Margin | 5.00% | 1.80% | -92.55% | -23.24% | -7.85% |
Free Cash Flow Margin | -1.15% | -9.85% | -20.69% | -39.73% | -53.87% |
EBITDA | -1,040 | -2,164 | -3,162 | -1,529 | -331.19 |
EBITDA Margin | -5.98% | -14.24% | -24.53% | -19.75% | -3.73% |
D&A For EBITDA | 2,326 | 2,177 | 1,908 | 1,800 | 1,536 |
EBIT | -3,365 | -4,341 | -5,069 | -3,330 | -1,868 |
EBIT Margin | -19.35% | -28.56% | -39.33% | -43.00% | -21.03% |
Advertising Expenses | - | 169.22 | 192.11 | 119.42 | 89.35 |